for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

United Therapeutics Corporation

UTHR.OQ

Latest Trade

109.38USD

Change

-1.14(-1.03%)

Volume

70,935

Today's Range

108.45

 - 

110.71

52 Week Range

75.67

 - 

127.77

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
110.52
Open
110.71
Volume
70,935
3M AVG Volume
10.75
Today's High
110.71
Today's Low
108.45
52 Week High
127.77
52 Week Low
75.67
Shares Out (MIL)
44.41
Market Cap (MIL)
4,847.55
Forward P/E
9.33
Dividend (Yield %)
--

Next Event

Q3 2020 United Therapeutics Corp Earnings Release

Latest Developments

More

United Therapeutics Corporation Reports Qtrly Non-Gaap Earnings Per Diluted Share $3.68

United Therapeutics Corporation Asserts New Tyvaso Patent Against Liquidia

United Therapeutics Says New Prescriptions From Treprostinil-Based Products Fell In April

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

Industry

Biotechnology & Drugs

Contact Info

1040 SPRING ST

SILVER SPRING, MD

20910

United States

+1.301.6089292

http://www.unither.com

Executive Leadership

Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

Michael Benkowitz

President, Chief Operating Officer

Christopher Patusky

Lead Independent Vice Chairman of the Board

James C. Edgemond

Chief Financial Officer, Treasurer

Paul A. Mahon

Executive Vice President, General Counsel, Corporate Secretary

Key Stats

2.20 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

1.7K

2018

1.6K

2019

1.4K

2020(E)

1.4K
EPS (USD)

2017

9.310

2018

13.390

2019

-2.390

2020(E)

10.852
Price To Earnings (TTM)
11.20
Price To Sales (TTM)
3.39
Price To Book (MRQ)
1.56
Price To Cash Flow (TTM)
10.10
Total Debt To Equity (MRQ)
25.86
LT Debt To Equity (MRQ)
25.86
Return on Investment (TTM)
11.62
Return on Equity (TTM)
10.59

Latest News

Latest News

BRIEF-Liquidia Responds To United Therapeutics Corporation Lawsuit

* LIQUIDIA RESPONDS TO UNITED THERAPEUTICS CORPORATION LAWSUIT

BRIEF-United Therapeutics Files Lawsuit Against Liquidia For Infringement Of Tyvaso Patents

* UNITED THERAPEUTICS CORP - FILES LAWSUIT AGAINST LIQUIDIA FOR INFRINGEMENT OF TYVASO PATENTS

BRIEF-Medicenna Therapeutics Expect To Complete IND Enabling Studies For MDNA109 Superkine Platform By Q1

* MEDICENNA THERAPEUTICS - END OF PHASE 2 MEETING PACKAGE FOR MDNA55 TO BE SUBMITTED IN Q2 2020

BRIEF-United Therapeutics Announces Additional Results From Freedom-Ev Study Showing Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertension

* UNITED THERAPEUTICS ANNOUNCES ADDITIONAL RESULTS FROM FREEDOM-EV STUDY SHOWING THE HEMODYNAMIC AND RISK STATUS REDUCTION BENEFITS OF ORENITRAM TREATMENT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

BRIEF-United Therapeutics Says Chairman And CEO Martine Rothblatt's 2019 Total Compensation Was $45.6 Mln Versus $16 Mln In 2018

* UNITED THERAPEUTICS CORP - CHAIRMAN AND CEO MARTINE ROTHBLATT'S 2019 TOTAL COMPENSATION WAS $45.6 MILLION VERSUS $16 MILLION IN 2018 - SEC FILING

BRIEF-Celularity Expands Strategic Collaboration With United Therapeutics

* CELULARITY EXPANDS STRATEGIC COLLABORATION WITH UNITED THERAPEUTICS CORPORATION TO COVID-19 INFECTION AND ACUTE RESPIRATORY DISTRESS SYNDROME

BRIEF-United Therapeutics Corporation Reports Q4 Adjusted Earnings Per Share $1.96

* ORATION REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

United Therapeutics notches win in fight over blocked generic rival

United Therapeutics Corp can continue to restrict how pharmacies dispense delivery devices for its cardiovascular drug Remodulin, a New Jersey federal judge ruled on Wednesday, dealing a setback to Novartis AG' Sandoz generic drug unit.

Arena Pharma soars on deal with United Therapeutics for hypertension drug

Shares of Arena Pharmaceuticals Inc jumped nearly 30 percent after the drug developer sold rights to develop and sell its hypertension treatment to United Therapeutics Corp, fetching it $800 million in an upfront payment.

BRIEF-United Therapeutics Reports Q1 Adj. Earnings Per Share Of $3.76

* Q1 EARNINGS PER SHARE VIEW $3.52 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-United Therapeutics To Acquire SteadyMed Ltd

* UNITED THERAPEUTICS-TRANSACTION, INCLUDING $75 MILLION IN CONTINGENT CONSIDERATION, IS VALUED AT $216 MILLION

BRIEF-United Therapeutics Says CEO Martine Rothblatt's FY 2017 Total Compensation Was $37.1 Mln

* UNITED THERAPEUTICS SAYS CEO MARTINE ROTHBLATT'S FY 2017 TOTAL COMPENSATION WAS $37.1 MILLION WHICH INCLUDED $33.1 MILLION IN OPTION/STAP AWARDS - SEC FILING

BRIEF-United Therapeutics Says FDA Accepted To Review Its NDA For Implantable System For Remodulin

* UNITED THERAPEUTICS- NOTIFIED BY FDA CO'S NDA FOR IMPLANTABLE SYSTEM FOR REMODULIN ACCEPTED FOR 6-MONTH REVIEW AS CLASS 2 RESUBMISSION - SEC FILING Source text: (https://bit.ly/2E6Hb6r) Further company coverage:

BRIEF-United Therapeutics Corp Reports Qtrly EPS Of $0.43

* Q4 EARNINGS PER SHARE VIEW $3.89, REVENUE VIEW $421.7 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-United Therapeutics Settles Patent Litigation With Actavis Laboratories FL

* UNITED THERAPEUTICS ANNOUNCES SETTLEMENT OF PATENT LITIGATION WITH ACTAVIS LABORATORIES FL, INC. RELATING TO ORENITRAM

BRIEF-Celularity Announces Formation Of Co With $250 Mln In Funding From Celgene, United Therapeutics, Others

* CELULARITY ANNOUNCES $250 MILLION IN FUNDING TO DELIVER TREATMENTS FOR CANCER, INFLAMMATORY AND DEGENERATIVE DISEASES, AND FUNCTIONAL REGENERATION

BRIEF-Corsair Pharma And United Therapeutics Enter Into Strategic Collaboration To Advance Novel Treprostinil Prodrugs

* CORSAIR PHARMA AND UNITED THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE NOVEL TREPROSTINIL PRODRUGS

United Therapeutics to pay $210 million to resolve U.S. kickback probe

United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

United Therapeutics to pay $210 mln to resolve U.S. kickback probe

United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

BRIEF-STEADYMED RECEIVES FAVORABLE RULING FROM U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT

* COURT OF APPEALS AFFIRMED A MARCH 31 RULING BY PATENT TRIAL & APPEAL BOARD INVALIDATING U.S. PATENT NO 8,497,393 OWNED BY UNITED THERAPEUTICS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up